An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Running, not enrolling · Phase 3

Conditions studied: Ulcerative Colitis

In brief

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 \[NCT03945188\] or APD334-302 \[NCT03996369\] or APD334-210 \[NCT04607837\]).

Key facts

Study ID
NCT03950232
Run by
Pfizer
People needed
896
Starts
2019-09-05
Expected to finish
2029-06-19
Last updated by the study team
2026-07-09

Who can join

Age: 16 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.